L3VLUP
ProSign in

ESTA · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ESTAJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ESTA
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterESTAJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20201 holders, $9.4m32 holders, $26.6bn
Q1 20212 holders, $24m31 holders, $25.3bn
Q2 20212 holders, $34m37 holders, $25.6bn
Q3 20212 holders, $24m40 holders, $24.1bn
Q4 20211 holders, $21m33 holders, $25.2bn
Q1 20221 holders, $20m35 holders, $28.2bn
Q2 20221 holders, $16m33 holders, $26.9bn
Q3 20222 holders, $19m36 holders, $25.4bn
Q4 20224 holders, $71m35 holders, $27.6bn
Q1 20232 holders, $57m42 holders, $24.5bn
Q2 20231 holders, $19m38 holders, $25.0bn
Q3 20231 holders, $14m37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 20242 holders, $75m32 holders, $19.7bn
Q2 20242 holders, $50m35 holders, $20.4bn
Q3 20241 holders, $64m28 holders, $22.3bn
Q4 20241 holders, $88m37 holders, $20.4bn
Q1 20253 holders, $111m32 holders, $20.5bn
Q2 20253 holders, $61m31 holders, $18.4bn
Q3 20253 holders, $54m32 holders, $23.7bn
Q4 20257 holders, $98m29 holders, $27.8bn
Q1 20264 holders, $14m34 holders, $35.6bn
Q2 20262 holders, $18m33 holders, $39.1bn
ESTA

Establishment Labs HLDGS Inc

Holders
0
Reported value
$0
Buyers
0
Sellers
1

Not ranked this quarter: its new positions are allocations in a new listing.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$19.0bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ESTA (0)

None.

Only JNJ (31)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, T. Rowe Price Associates Inc, Tudor Investment Corp, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →